Sign In
Buy ALPMY
$13.40
-0.200 (-1.47%)
At Close: Jun 03, 2026
XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI
- Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy- - If approved, enfortumab
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
08:30am, Tuesday, 26'th Mar 2024
Permanent J-code J2782 effective April 1, 2024 NORTHBROOK, Ill. , March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today annou
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
08:00am, Tuesday, 26'th Mar 2024
VYLOY approved in combination with chemotherapy for patients with human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer MHLW a
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
08:00am, Friday, 22'nd Mar 2024
- If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient populations in
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
05:27am, Monday, 11'th Mar 2024
DUNDEE, Scotland--(BUSINESS WIRE)--Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unme
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
06:31pm, Sunday, 03'rd Mar 2024
TOKYO , March 3, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced dosing of the first patient in the STARLIGHT™ 2 Phase 3 pivotal s
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
06:30pm, Thursday, 15'th Feb 2024
- Innovative universal, off-the-shelf in vivo CAR-T Cell therapy - TOKYO and BOSTON , Feb. 15, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and
Astellas Makes Announcement about Management Structure
06:30pm, Tuesday, 06'th Feb 2024
TOKYO , Feb. 6, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its management structure effective April
Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl
07:00am, Thursday, 01'st Feb 2024
Astellas is returning to the Super Bowl to help educate game viewers about VEOZAH and vasomotor symptoms (VMS), the most commonly reported menopause symptoms 1 The "Fewer Hot Flashes, More Not Flashes
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy – – If approved, PA
Astellas Announces Strategic Collaboration with Mass General Brigham
06:30pm, Tuesday, 30'th Jan 2024
- Five-year collaboration to advance translational medicine and accelerate early development of novel therapies -- Focus on oncology, rare disease, and cell and gene therapies - TOKYO , Jan. 30, 2024
US FDA declines to approve Astellas' gastric cancer drug
07:01pm, Monday, 08'th Jan 2024
Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues related to a third-par
Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.
06:30pm, Monday, 08'th Jan 2024
TOKYO , Jan. 8, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) issued a complete respon
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager
12:53am, Thursday, 28'th Dec 2023
SHANGHAI and SUZHOU, China and TOKYO , Dec. 28, 2023 /PRNewswire/ -- Elpiscience Biopharma, Ltd. (Chairman and CEO: Darren Ji, MD, Ph.D.
